Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors

Area of Science:

• Oncology
• Cancer Biology
• Immunotherapy

Background:

• Genomic instability, a cancer hallmark, stems from DNA damage response (DDR) deficiencies.
• Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) exploit DDR defects, inducing synthetic lethality in cancers with BRCA mutations or homologous recombination deficiencies (HRD).
• Immune checkpoint inhibitors (ICIs) offer potent antitumor effects but face primary or acquired resistance.

Purpose of the Study:

• To review the rationale and evidence for combining PARPi and ICIs in cancer treatment.
• To explore how PARPi influences the tumor immune microenvironment to enhance ICI efficacy.
• To summarize preclinical findings and early clinical trial data on this combination strategy.

Main Methods:

• Review of basic and translational research on PARPi and ICI synergy.
• Analysis of preclinical studies investigating combined PARPi and ICI treatment.
• Summary of early clinical trial data evaluating the combination therapy.

Main Results:

• PARPi induces unrepaired DNA damage, potentially enhancing anti-tumor immunity and ICI responsiveness.
• Preclinical data and early clinical trials suggest synergistic effects between PARPi and ICIs.
• The combination strategy shows promise in overcoming resistance to single-agent therapies.

Conclusions:

• Combining PARPi and ICIs is a rational strategy for cancer treatment, particularly in tumors with DDR deficiencies.
• This combination may overcome resistance mechanisms and improve patient outcomes.
• Further research and clinical trials are needed to optimize the use and understand the limitations of this approach.